Peyronie´s disease

Authors: L. A. Levine;  F. L. Taylor
Published in: Urol List 2008; 6(4): 5-17


Peyronie's disease is believed to be a wound healing disorder resulting in a fibrous inelastic scar resulting in a variety of penile dysfunctions. This includes deformity in the erect state, shortening, narrowing, indentations, pain and is frequently associated with erectile dysfunction. Historical reviews have suggested that Peyronie's disease is rare and tends to resolve spontaneously. More recent demographic and natural history studies have demonstrated that Peyronie's disease has been reported to occur in 4–9 % of adult males and rarely resolves spontaneously. As a result of the deformity and associated sexual dysfunction this disorder can be devastating both physically and psychologically. This article will review the history, current understanding of pathophysiology, epidemiology, and recommended patient evaluation. There will also be a review of current non-surgical and surgical treatment options. The goal is to familiarize the practicing urologist with the contemporary approach to Peyronie's disease with hopes that this will guide more effective treatment, as well as a better understanding of this devastating disorder.

Key words:
Peyronie's disease, penile deformity, erectile dysfunction, injection therapy, traction therapy


1. La Peyronie F. Sur quelques obstacles qui s'opposent á l'éjaculation naturelle de la semence. Mem Acad Royale Chir 1743; 1: 337–342.

2. Akkus E. Historical Review of Peyronie's Disease. In: Laurence A. Levine. Peyronie's Disease: a guide to clinical management. New Jersey: Humana Press 2007.

3. Borgogni T. Cyrurgia Edita et Compilata. Venice, 1498 (written 1265–1275).

4. Murphy LJT. Miscellanea: Peyronie's disease (fibrous cavernositis). In: Ch. C. Thomas. The History of Urology. 1st ed. Illinois: Springfield 1972: 485–486.

5. Wesson MD. Peyronie's disease (plastic induration) cause and treatment. J Urol 1943; 49: 350–356.

6. Devine et al. Proposal: trauma as the cause of the Peyronie's lesion. J Urol 1997; 157(1): 285–290.

7. Zargooshi et al. Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma. J Urol 2004; 172(1): 186–188.

8. Feiken E, Romer J, Eriksen J et al. Neutrophils expresstumor necrosis factor-alpha during mouse skin wound healing. J Invest Dermatol 1995; 105: 120.

9. DiPietro LA. Wound healing: The role of the macrophage and other immune cells. Shock 1995; 4: 233.

10. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair. Int J Mol Med 2000; 6: 391–407.

11. El Sakka AI, Hassoba HM, Chui RM. An animal model of Peyronie's like condition associated with an increase of transforming growth factor β mRNA and protein expression. J. Urol 1997; 158: 2284– 2290.

12. El Sakka AI, Hassoba HM, Pillarisetty RJ et al. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391–1394.

13. Bivalacqua TJ, Champion HC, Leungwattanakij S et al. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's like condition in the rat. J Androl 2001; 22: 497–506.

14. Kucharewicz I, Kowal K, Buczko W et al. The plasmin system in airway remodeling. Thromb Res 2003; 112: 1–7.

15. Van de Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol 1997; 157: 306–310.

16. Davila H, Magee TR, Rajfer J et al. Peyronie's disease is associated with an increase of plasminogen activator inhibitor-1 in fibrotic plaque. Urology 2005; 65: 645–648.

17. Davila H, Ferrini M, Rajfer J et al. Fibrin induction of a Peyronie's-like plaque in the rat penile tunica albuginea. BJU Int 2003; 91: 830–838.

18. Ryu JK, Piao S, Shin HY, et al. IN-1130, A Novel Transforming Growth Factory Type 1 Receptor Kinase (ALK 5) Inhibitor Regresses Fibrotic Plaque and Corrects Penile Curvature in a Rat Model of Peyronie's Disease. [Abst 749]. Annual Meeting of the American Urological Association; 2007.

19. Del Carlo M, Levine LA, Cole AA. Differential regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) by interleukin-1– (IL-1–) and transforming growth factor β (TGF- β in Peyronie's fibroblasts). Abstract, 2007 AUA Meeting.

20. Qian A, Meals RA, Rajfer J et al. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004; 64(2): 399–404.

21. Polkey HJ. ID induratio penis plastica. Urol Cut Rev 1928; 32: 287–308.

22. Ludvik W, Wasserburger K. Die Radiumbehandlung der induration penis plastica. Z Urol Nephrol 1968; 61: 319–325.

23. Devine CJ. Introduction to Peyronie's Disease. J Urol 1997; 157: 272–275.

24. Linday MB et al. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146: 1007–1009.

25. Sommer F et al. Epidemiology of Peyronie's disease. Int J Impot Res 2002; 14: 379–383.

26. Mulhall JP, Creech SD, Boorjian SA et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171: 2350– 2353.

27. La Rochelle JC, Levine LA. A Survey of Primary- Care Physicians and Urologists Regarding Peyronie's Disease. J Sex Med; 4: 1167–1173.

28. Levine LA, Estrada CR, Storm DW et al. Peyronie's disease in younger men: Characteristics and treatment results. J Androl 2003; 24: 27–32.

29. Tefekli A, Kandirali E, Erol H et al. Peyronie's disease in men under 40: characteristics and outcome. Int J Impot Res 2001; 13: 18–23.

30. Briganti A et al. Clinical presentation of Peyronie's disease in young patients. Int J Impt Res 2003; 15: S44–47.

31. Deveci S, Hopps CV, O'Brien K et al. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007; 4(2): 485–490.

32. Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol 1970; 103: 75.

33. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376– 1379.

34. Kadioglu A et al. A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 1075–1079.

35. Akin-Olugbade Y, Mulhall JP. The medical management of Peyronie's disease. Nature Clinical Practice Urology 2007; 4(2): 95–103.

36. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie's disease. International Journal of Impotence Research 2003; 15(5): S103–112.

37. Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948; 41: 173–177.

38. Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002; 14: 353–360.

39. Gholami SS, Gonzalez-Cadavid NF, Lue TF et al. Peyronie's disease: a review. J Urol 2002; 169: 1234– 1241.

40. Pryor JP, Farell CF. Controlled clinical trial of Vitamin E in Peyronie's disease. Prog Reprod Biol 1983; 9: 41–45.

41. Akkus E, Carrier S, Rehman J et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291–295.

42. Kadioglu A, Tefekli A, Koksal T et al. Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169–175.

43. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004;16: 238–243.

44. Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol 1959; 81: 770–772.

45. Hasche-Klunder R. Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTABA) (author's transl). Urologe A 1978; 17: 224–227.

46. Weidner W, Schroeder-Printzen I, Rudnick J et al. Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J Urol 1999; 6: 205.

47. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530–535.

48. Ralph DJ, Brooks MD, Bottazzo GF et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648–651.

49. Colletta AA, Wakefield LM, Howell FV et al. Antioestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Caner 1990; 62: 405–409.

50. Teloken C, Rhoden EL, Grazziotin TM et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999; 162: 2003–2005.

51. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs. tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88: 63–67.

52. Valente EG, Vernet D, Ferrini M et al. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229–244.

53. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3: 111–115.

54. Martin DJ, Badwan K, Parker M et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168: 2483–2485.

55. Fitch WP, Easterling J, Talbert RL et al. Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie's Disease – A Placebo-Controlled Pilot Study. J Sex Med 2007; 4: 477–484.

56. Levine LA. Comment on Topical Verapamil HCl, Topical Trifluoperazine, and Topical Magnesium Sulfate for the Treatment of Peyronie's Disease – A Placebo- Controlled Pilot Study. J Sex Med 2007; 4: 1081– 1082.

57. Bodner H, Howard AH, Kaplan JH. Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 1954; 400–403.

58. Winter CC, Khanna R. Peyronie's disease: results with dermo-jet injection of dexamethasone. J Urol 1975; 114(6): 898–900.

59. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol 1980; 52: 392–395.

60. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982; 10: 135–140.

61. Gelbard MK, Linkner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 280–283.

62. Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J Urol 1993; 149: 56–58.

63. Roth M, Eickelberg O, Kohler E et al. Ca2 + channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 5748–5482.

64. Mulhall JP, Anderson MS, Lubrano T et al. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397–405.

65. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522–1524.

66. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long term single-blind study. Urology 1998; 51: 620–626.

67. Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie's disease: a review. Int J Impot Res 2002; 14: 324–328.

68. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil Prevents the Progression of Peyronie's Disease. Urology 2007; 69: 1181–1184.

69. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferonsalpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89–94.

70. Wegner HE, Andreson R, Knipsel HH et al. Treatment of Peyronie's disease with local interferon-alpha- 2b. Eur Urol 1995; 28: 236–240.

71. Wegner HE, Andresen R, Knipsel HH et al. Local interferon-alpha-2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32: 190–193.

72. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999; 20: 444–448.

73. Dang G, Matern R, Bivalacqua TJ et al. Intralesional interferon-alpha-2b injections for the treatment of Peyronie's disease. South Med J 2004; 97: 42–46.

74. Hellstrom WJ, Kendirici M, Matern R et al. Singleblind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon- alpha-2b for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394–398.

75. Levine LA. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003; 15: S113–120.

76. Hauck EW, Altinkilic BM, Ludwig M et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 2000; 38: 663–669.

77. Hatzichristodoulou G, Meisner C et al. Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in patients with Peyronie's disease (PD) ? first results of a prospective, randomized, placebo-controlled, singleblind study. [Abst 993] Annual Meeting of the American Urological Association; 2006.

78. Hatzichristodoulou G, Meisner C et al. Efficacy Of Extracorporeal Shock Wave Therapy On Plaque Size And Sexual Function In Patients With Peyronie's Disease – Results of a Prospective, Randomized, Placebo- Controlled Study. [Abst. 747] Annual Meeting of the American Urological Association; 2007.

79. Riedl CR, Plas E, Engelhard P et al. Iontophoresis for treatment of Peyronie's disease. J Urol 2000; 163: 95–99.

80. Montorsi F, Salonia A, Guazzoni G et al. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Androl 2000; 21: 85–90.

81. Di Stasi SM, Giannantoni A, Capelli G et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003; 91: 825–829.

82. Di Stasi SM, Giannantoni A, Stephen RL et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004; 171: 1605–1608.

83. Levine LA, Estrada CR, Show W et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169: 1775–1778.

84. Greenfield JM, Shah SJ, Levine LA. Verapamil vs. saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial. J Urol 2007; 177: 972–975.

85. Ojingwa JC, Isseroff RR. Electrical stimulation of wound healing. J Invest Dermatol 2003; 121: 1–12.

86. Preito Castro RM, Leva Vallejo ME, Regueiro Lopez JC et al. Combined treatment with vitamin E and colchicines in the early stages of Peyronie's disease. BJU Int 2003; 91: 522–524.

87. Mirone V, Palmieri A, Granata AM et al. Ultrasound- Guided ESWT in Peyronie's disease plaques. Arch Ital Urol Androl 2000; 72: 384–387.

88. Mirone V, Imbimbo C, Palmieri A et al. Our experience on the association of a new physical and medical therapy in patients suffering from induration penis plastica. Eur Urol 1999; 36: 327–330.

89. Cavallini G, Biagiotti G, Koverech A et al. Oral propionyl- l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89: 895–900.

90. Levine LA, Lenting EL. Experience with a surgical algorithm for Peyronie's disease. J Urol 1997; 158: 2149–2152.

91. Moncada I, Jara J, Marinez J et al. Managing Penile Shortening After Peyronie's Disease Surgery. [Abst 750] Annual Meeting of the American Urological Association; 2007.

92. Taylor FL, Levine LA. Surgical Correction of Peyronie's Disease via Tunica Albuginea Plication or Plaque Partial Excision with Pericardial Graft: Long Term Follow-Up. [Abst 748 ] Annual Meeting of the American Urological Association; 2007.

93. Kadioglu A, Sanli O, Akman T et al. Graft materials in Peyronie's disease surgery: a comprehensive review. J Sex Med 2007; 4: 581–595.

94. Greenfield JM, Estrada CR, Levine LA. Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med 2005; 2: 241–247.

95. Carson CC, Hodge GB, Anderson EE. Penile prosthesis in Peyronie's disease. Br J Urol 1983; 55: 417–421

96. Ghanem HM, Fahmy I, El Meliegy A. Malleable penile implants without plaque surgery in the treatment of Peyronie's disease. Int J Impot Res 1998; 10: 171–173.

97. Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie's disease. Int J Impot Res 2000; 12: 147–151.

98. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a two center study. J Urol 2001; 166: 932–937.

99. Montague DK, AngermeierKW, Lakin MM, Ingleright BJ. AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie's disease: comparison of CX and Ultrex cylinders. J Urol 1996; 156: 1633–1635.

100. Dowalczyk JJ, Mulcahy JJ. Penile curvatures and aneurismal defects with the Ultrex penile prosthesis corrected with insertion of the AMS 700CX. J Urol 1996; 156: 398–401.

101. Montorsi F, Rigatti P, Carmignani G et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol. 2000; 37: 50–55.

Literatura k tabulce 2

1. Daitch JA, Angermeier KW, Montague DK. Modified corporoplasty for penile curvature: long-term results and patient satisfaction. J Urol 1999; 162: 2006– 2009.

2. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 2002; 167: 2066–2069.

3. Syed AH, Abbasi Z, Hargreave TB. Nesbit procedure for disabling Peyronie's curvature: a median follow-up of 84 months. Urology 2003; 61: 999–1003.

4. Savoca G, Scieri F, Pietropaolo F et al. Straightening corporoplasty for Peyronie's disease: a review of 218 patients with median follow-up of 89 months. Eur Urol 2004; 6: 610–614.

5. Rolle L, Tamagnone A, Timpano M et al. The Nesbit operation for penile curvature: an easy and effective technical modification. J Urol 2005; 173: 171–173.

6. Bella AJ, Beasley KA, Obied A, Brock GB. Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. Urology 2006; 68: 852–857.

7. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol 2006; 175: 238–241.

Literatura k tabulce 3

1. Gelbard MK. Relaxing incisions in the correction of penile deformity due to Peyronie's disease. J Urol 1995; 154: 1457–1460.

2. El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie's disease. Part II: outcome analysis. J Urol 1998; 160: 2050–2053.

3. Hatzichristou DG, Hatzimouratidis K, Apostolidis A et al. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol 2002; 167: 1367–1370.

4. Egydio PH, Lucon AM, Arap S. Treatment of Peyronie's disease by incomplete circumferential incision of the tunica albuginea and plaque with bovine pericardium graft. Urology 2002; 59: 570–574.

5. Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie's disease. J Urol 2003; 170: 2359–2362.

6. Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie's disease. BJU Int 2005; 95: 1029–1033.

7. Breyer BN, Brant WO, Garcia MM et al. Complications of porcine small intestine submucosa graft for Peyronie's disease. J Urol 2007; 177: 589–591.

8. Hsu GL, Chen HS, Hsieh CH et al. Long-term results of autologous venous grafts for penile morphological reconstruction. J Androl 2007; 28: 186–193.

Paediatric urologist Urology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account